{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:17:18Z","timestamp":1788351438667,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014901","name":"Hubei University of Arts and Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014901","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology in Vitro"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.tiv.2026.106294","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:10:21Z","timestamp":1786547421000},"page":"106294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Efficacy, safety, and mitochondrial mechanisms of myricetin in a preclinical model of trastuzumab-resistant HER2+ breast cancer"],"prefix":"10.1016","volume":"117","author":[{"given":"Yaqing","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gege","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiling","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tiv.2026.106294_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101608","article-title":"Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure","volume":"8","author":"Antonarelli","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.tiv.2026.106294_bb0010","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1158\/1078-0432.CCR-17-3070","article-title":"Oxidative phosphorylation as an emerging target in cancer therapy","volume":"24","author":"Ashton","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tiv.2026.106294_bb0015","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s11864-024-01277-2","article-title":"Updates in treatment of HER2-positive metastatic breast cancer","volume":"25","author":"Avelino","year":"2024","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.tiv.2026.106294_bb0020","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/CAD.0000000000001421","article-title":"Myricetin is effective and selective in inhibiting imatinib-resistant chronic myeloid leukemia stem and differentiated cells through targeting eIF4E","volume":"34","author":"Cai","year":"2023","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.tiv.2026.106294_bb0025","doi-asserted-by":"crossref","DOI":"10.1002\/imo2.19","article-title":"A glimpse into the future: integrating artificial intelligence for precision HER2-positive breast cancer management","volume":"1","author":"Deng","year":"2024","journal-title":"IMetaOmics"},{"key":"10.1016\/j.tiv.2026.106294_bb0030","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1016\/j.febslet.2008.09.024","article-title":"Enhanced glycolysis induced by mtDNA mutations does not regulate metastasis","volume":"582","author":"Ishikawa","year":"2008","journal-title":"FEBS Lett."},{"key":"10.1016\/j.tiv.2026.106294_bb0035","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ccr.2011.10.028","article-title":"Power cut: inhibiting mitochondrial translation to target leukemia","volume":"20","author":"Jaras","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tiv.2026.106294_bb0040","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.fct.2018.05.005","article-title":"Myricetin-induced apoptosis of triple-negative breast cancer cells is mediated by the iron-dependent generation of reactive oxygen species from hydrogen peroxide","volume":"118","author":"Knickle","year":"2018","journal-title":"Food Chem. Toxicol. Int. J. Published for the British Industrial Biological Research Association"},{"key":"10.1016\/j.tiv.2026.106294_bb0045","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells","volume":"12","author":"Lagadinou","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.tiv.2026.106294_bb0050","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.905","article-title":"Anticancer effects of myricetin derivatives in non-small cell lung cancer in vitro and in vivo","volume":"10","author":"Li","year":"2022","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.tiv.2026.106294_bb0055","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1158\/0008-5472.CAN-23-4066","article-title":"Molecular characterization and classification of HER2-positive breast cancer inform tailored therapeutic strategies","volume":"84","author":"Li","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.tiv.2026.106294_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpha.2024.101075","article-title":"Natural products based on correa\u2019s cascade for the treatment of gastric cancer trilogy: current status and future perspective","volume":"15","author":"Liao","year":"2025","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.tiv.2026.106294_bb0065","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.bbrc.2016.10.064","article-title":"Anthelmintic drug ivermectin inhibits angiogenesis, growth and survival of glioblastoma through inducing mitochondrial dysfunction and oxidative stress","volume":"480","author":"Liu","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.tiv.2026.106294_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27238367","article-title":"Natural products as anticancer agents: current status and future perspectives","volume":"27","author":"Naeem","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.tiv.2026.106294_bb0075","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ccr.2006.10.008","article-title":"A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes","volume":"10","author":"Neve","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tiv.2026.106294_bb0080","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1021\/acs.jnatprod.9b01285","article-title":"Natural products as sources of new drugs over the nearly four decades from 01\/1981 to 09\/2019","volume":"83","author":"Newman","year":"2020","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.tiv.2026.106294_bb0085","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ddr.20276","article-title":"Natural products and colon cancer: current status and future prospects","volume":"69","author":"Rajamanickam","year":"2008","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.tiv.2026.106294_bb0090","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1089\/ars.2016.6677","article-title":"Selective disruption of respiratory supercomplexes as a new strategy to suppress Her2(high) breast cancer","volume":"26","author":"Rohlenova","year":"2017","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.tiv.2026.106294_bb0095","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.31557\/APJCP.2020.21.12.3461","article-title":"Myricetin exerts its apoptotic effects on MCF-7 breast cancer cells through evoking the BRCA1-GADD45 pathway","volume":"21","author":"Sajedi","year":"2020","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.tiv.2026.106294_bb0100","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s12032-023-02274-5","article-title":"Nanoemulsion potentiates the anti-cancer activity of myricetin by effective inhibition of PI3K\/AKT\/mTOR pathway in triple-negative breast cancer cells","volume":"41","author":"Sharma","year":"2024","journal-title":"Med. Oncol."},{"key":"10.1016\/j.tiv.2026.106294_bb0105","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12906-020-02900-z","article-title":"Effect of gallic acid and myricetin on ovarian cancer models: a possible alternative antitumoral treatment","volume":"20","author":"Varela-Rodriguez","year":"2020","journal-title":"BMC Complement. Med. Ther."},{"key":"10.1016\/j.tiv.2026.106294_bb0110","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/nature13611","article-title":"Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function","volume":"514","author":"Viale","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.tiv.2026.106294_bb0115","article-title":"Trastuzumab resistance in HER2-positive breast cancer: mechanisms, emerging biomarkers and targeting agents","volume":"12","author":"Wang","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.tiv.2026.106294_bb0120","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00280-025-04770-z","article-title":"Napabucasin targets resistant triple negative breast cancer through suppressing STAT3 and mitochondrial function","volume":"95","author":"Yuan","year":"2025","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.tiv.2026.106294_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010062","article-title":"The effect of oxidative phosphorylation on cancer drug resistance","volume":"15","author":"Zhao","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.tiv.2026.106294_bb0130","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1038\/s41467-022-30217-7","article-title":"N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer","volume":"13","author":"Zou","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tiv.2026.106294_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101126","article-title":"crVDAC3 alleviates ferroptosis by impeding HSPB1 ubiquitination and confers trastuzumab deruxtecan resistance in HER2-low breast cancer","volume":"77","author":"Zou","year":"2024","journal-title":"Drug Resist. Updat."}],"container-title":["Toxicology in Vitro"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887233326001025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887233326001025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:35:26Z","timestamp":1788348926000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887233326001025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":27,"alternative-id":["S0887233326001025"],"URL":"https:\/\/doi.org\/10.1016\/j.tiv.2026.106294","relation":{},"ISSN":["0887-2333"],"issn-type":[{"value":"0887-2333","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy, safety, and mitochondrial mechanisms of myricetin in a preclinical model of trastuzumab-resistant HER2+ breast cancer","name":"articletitle","label":"Article Title"},{"value":"Toxicology in Vitro","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tiv.2026.106294","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106294"}}